% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{GarcaMegas:299790,
      author       = {I. García Megías and L. S. Almeida and A. K. Calapaquí
                      Terán and K. M. Pabst$^*$ and K. Herrmann$^*$ and F.
                      Giammarile and R. C. Delgado Bolton},
      title        = {{FAPI} radiopharmaceuticals in nuclear oncology and
                      theranostics of solid tumours: are we nearer to surrounding
                      the hallmarks of cancer?},
      journal      = {Annals of nuclear medicine},
      volume       = {39},
      issn         = {0914-7187},
      address      = {[Erscheinungsort nicht ermittelbar]},
      publisher    = {Springer Japan},
      reportid     = {DKFZ-2025-00545},
      pages        = {407–423},
      year         = {2025},
      note         = {Volume 39, pages 407–423, (2025)},
      abstract     = {[18F]FDG PET/CT is the most widely used PET
                      radiopharmaceutical in oncology, but it is not exempt of
                      diagnostic limitations. FAPI have emerged as a great tool in
                      the management of several different solid tumours in which
                      [18F]FDG is not able to provide enough information. The aim
                      of this work was to evaluate the available evidence on
                      diagnostic and therapeutic applications of PET/CT with FAPI
                      radiopharmaceuticals. We underwent a non-systematic review
                      focusing in the utility of FAPI radiopharmaceuticals in
                      PET/CT diagnosis and in the treatment of several
                      malignancies. FAPI radiopharmaceuticals present
                      characteristics that can potentially overcome some known
                      diagnostic limitations of [18F]FDG. FAPI
                      radiopharmaceuticals present a high target-to-background
                      ratio (TBR) in many solid tumours such as oesophageal
                      cancer, gastric cancer, pancreatic cancer, hepatic cancer,
                      colorectal cancer, breast cancer, ovarian, cervical cancer,
                      and head and neck cancer. Available evidence suggests the
                      high TBR improves sensitivity and specificity compared to
                      [18F]FDG, especially for the detection of lymphadenopathies
                      and peritoneal metastases, and may improve patient
                      management and radiation treatment planning. Moreover, it is
                      important to underline the potential theranostic application
                      of FAPI radiopharmaceuticals.},
      subtyp        = {Review Article},
      keywords     = {Cancer (Other) / FAPI (Other) / Nuclear oncology (Other) /
                      PET/CT (Other) / Radiopharmaceutical therapy (Other) /
                      Theranostic (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40069442},
      doi          = {10.1007/s12149-025-02022-x},
      url          = {https://inrepo02.dkfz.de/record/299790},
}